USE OF iSGLT2 IN THE TREATMENT OF PATIENTS WITH HEART FAILURE AND DIABETES MELLITUS

• DOI: 10.22533/at.ed.159372321012

• Palavras-chave: SGLT2, Heart failure, Diabetes mellitus.

• Keywords: SGLT2, Heart failure, Diabetes mellitus.

• Abstract:

  Purpose:  to evaluate the favorable and unfavorable results in the use of sodium glucose-SGLT2 cotransporter inhibitors such as empagliflozin and dapagliflozin in the treatment of type 2 diabetes mellitus (DM2) and heart failure (HF) patients Methods: An integrative review was carried out, using as criteria the search in the National Library of Medicine (PubMed) and Scientific Electronic Library Online (SciELO) databases using the descriptors (i) iSGLT2 (ii) Heart failure, (iii) Diabetes mellitus, with the Boolean operator “AND”. Studies published from 2018 to 2023 were included. Results: There is a need for better therapies to reduce damage to target organs and symptoms. A group of drugs that have shown promise are the type II sodium glucose cotransporter inhibitors, studies show that dapagliflozin mainly reduced cardiovascular risks and death from cardiovascular causes in patients with heart failure, reducing renal outcomes, with the latest anti-diabetic drugs approved by the Food and Drug Administration (FDA) with high efficacy for the control of both pathologies and which are safe to use, reducing negative outcomes, allowing these patients to have a better quality of life.